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SUPPLEMENTAL MATERIAL 
Morning plasma cortisol as a cardiovascular risk factor: findings from prospective 
cohort and Mendelian randomization studies 
Supplemental Methods 
The Northern Sweden VIP, MONICA and MSP studies 
Cases were identified by cross linkage between the MONICA myocardial infarction (MI) and stroke registries 
and the survey cohorts (VIP, MONICA and MSP), and controls from the survey cohorts were matched for sex, 
age, survey type and date of survey.  
VIP is an ongoing community intervention program targeting cardiovascular disease and diabetes prevention.1 
Participants are asked to participate in a health survey at their primary health centre at the ages of 30, 40, 50, 
and 60 years. However, those aged 30 are no longer invited because of a lack of resources. The participation rate 
was initially 55% but has increased and is now approximately 65%. The total number of unique individuals 
surveyed in VIP was 99,268 as of 31 December 2014.  
MONICA consists of randomly selected individuals aged 25–74 years from the counties of Västerbotten and 
Norrbotten who were invited to participate in a health study. The study has been repeated seven times at 
approximately 5-year intervals with new random samples of 2500 individuals each (the first two surveys invited 
2000 individuals each).2 For each survey 250 men and 250 women from each 10-year age group were randomly 
sampled from population registers, stratified for age and sex. The overall participation rate was 74%, and a total 
of 12,368 unique persons had participated by 31 December 2014. 
Data for the MSP cohort, consisting of 28,778 women, were collected between 1995 and 2006 when the women 
attended their regular mammography examination and were asked to donate blood samples for research. In 
addition, anthropometric measurements were taken. 
In all studies, participants were asked to donate blood to be stored at -80°C for future research. Participants 
were fasting before sampling for a minimum of 4 hours (extended to 8 hours in 1992). 
Since 1985, all (in-hospital and out-of-hospital) cases with acute stroke (in the age group 25–74 years) and acute 
MI (in the age group 25–64 years) in the MONICA area (i.e., Västerbotten and Norrbotten) have been included 
in the Northern Sweden MONICA registries using WHO criteria and MONICA methodology. Possible CVD 
events (fatal and non-fatal CVD (MI or stroke)) were identified through screening of hospital discharge records, 
general practitioners’ reports, and death certificates, with ICD 8 and 9 codes 410-413 and 430-438 
corresponding to ICD 10 codes I20-I24 and I60-69. For death certificates, the codes 414 and 798–799 (ICD 8 
and 9), and I25 and R96–99 (ICD 10) were also included. Data collection included information on medical 
history, symptoms, examinations, presenting electrocardiogram (ECG), and stroke subtypes. The number of 
subjects with MI and stroke included in the Northern Sweden MONICA registry not willing to participate in 
further studies has averaged two to six per year (0.2–0.6 %). 
Detailed descriptions of criteria for diagnosis of stroke and classification of subtypes have been published.3,4 In 
short, stroke cases were classified into one of the categories “definite stroke”, “unclassified stroke”, or “no 
stroke”. Unclassified events were mostly fatal cases with a death certificate diagnosis of stroke where 
information on previous history of stroke or of the clinical event was not obtainable. In this study, only cases 
classified as “definite stroke” have been included in nonfatal events. In fatal events, the category “unclassifiable 
stroke” has also been included, in accordance with the agreed convention in the core MONICA project.  
 
British Women’s Heart and Health Study (BWHHS) 
Women from the main cohort with CHD at baseline (N = 694 prevalent cases; 16.2%) were excluded. Incident 
cases of CHD (169 cases, 111 non-fatal and 58 fatal) were identified by two-yearly medical record reviews and 
through routine death registration until October 2016, defined as either of: (i) death with an underlying or 
contributing cause of CHD (ICD10 codes I20-I25, I51.6); or (ii) a MI (defined according to WHO criteria), first 
diagnosis of angina or coronary artery by-pass or angioplasty. For each case, two controls were randomly 
selected, within 5-year age groups of the cases, from women without CHD at the baseline assessment and who 
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had been followed-up over the same time period as the cases without experiencing a CHD event. Additional 
controls were selected to replace those who subsequently died or experienced a CHD event within 1 year of the 
selection. 
Additional analyses of prospective cohort studies 
Additional analyses were performed to investigate whether the effect of cortisol on CVD differed by sex. 
Similarly, the outcome was stratified to investigate the effect of cortisol on CHD and stroke separately. The 
equality of coefficients from these stratified analyses were formally tested using the generalized Hausman 
specification test.5 
Methods for dealing with missing data 
In order to increase efficiency and minimise selection bias we used multivariate multiple imputation to impute 
missing data for potential confounders including all exposures, covariables, outcomes and potential predictors of 
missing data in the imputation equations.6 This assumes the missing data can be explained by the observed data 
(missing at random assumption).7 It is not possible to test this assumption, but we have included all exposures, 
outcomes, covariables and any variables that are predictive of missing data in our imputation models in order to 
increase the plausibility that it is correct. Table S6 lists the variables included in these missing data prediction 
models and how they were entered into the models.  In Stata, we carried out 20 cycles of regression switching as 
described by Royston6 and generated 20 imputation datasets. The multiple imputation approach creates a 
number of copies of the data (in this case, 20 copies) in which missing values are imputed, with an appropriate 
level of randomness, by chained equations. The average estimate from each of these 20 datasets is obtained 
using Rubin’s rules taking account of the uncertainty in the imputation so that the standard errors for any 
regression coefficients (used to calculate p-values and 95% confidence intervals) take account of uncertainty in 
the imputations as well as uncertainty in the estimate. 
Multivariable regression of prospective studies meta-analysis 
The Caerphilly study includes 2512 men (2323 with cortisol data) from the town of Caerphilly or surrounding 
villages examined between 1979 and 1983.8 The majority of fasting blood samples were taken between 0700h 
and 0800h. The records of all men at the National Health Service Central Registry were flagged so that 
notification of death was automatic and a copy of the death certificate was received. Fatal ischaemic heart 
disease (IHD) events were classified as deaths with International Classification of Diseases 9 (ICD-9) codes 410 
to 414. Non-fatal IHD events were ascertained through follow-up clinics and discharges from local hospitals 
with a diagnosis code of ICD-9 410 to 414.  
The Vietnam Experience study consists of 18313 male former military personnel (4255 with cortisol data)9. All 
fasting blood samples were taken in the morning. Mortality due to CVD was classified using ICD-9 codes: 390–
434 and 436–448, and ICD-10 codes: I00–I78. The majority of deaths were from IHD.  
Sensitivity analyses of the multivariable regression of prospective studies meta-analysis 
We undertook a leave one out analysis, in which the meta-analysis was repeated four times with one study 
removed each time, to explore whether any differences between study results importantly influenced the pooled 
estimate. To assess potential small study bias, a funnel plot was prepared of lnOR against the standard error 
lnOR10 and analysed using Egger’s test.11 
One-sample Mendelian randomization 
The causal estimate was derived using the two-stage method comprising a first-stage regression of the exposure 
on the SNP, and a second-stage regression of the outcome on the fitted values of the exposure from the first 
stage. As cortisol measurements were taken at baseline (prior to onset of CVD) then the first stage (SNP-
cortisol) association was obtained using cases and controls.12 . We included covariates in the first-stage and 
second-stage regressions. This increases efficiency and hence the precision of the causal estimate. However, it 
may lead to bias in the causal estimate if a covariate is on the causal pathway between exposure and outcome or 
is a collider or causally downstream of a collider.13 
Two-sample Mendelian randomization 
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This approach assumes that the gene-exposure and gene-outcome associations are estimated in non-overlapping 
samples and are representative of the same population (similar age, sex distribution and the same ethnic 
group).18 For our analyses there are no studies that contributed to both CORNET and CARDIoGRAM and so we 
can rule out a large overlap. A proportion of participants of the ORCADES study, which contributed to 
CORNET, were eligible to participate in UK Biobank. We are unable to rule out the possibility that individuals 
may have participated in multiple studies and so may have contributed to CORNET and to CARDIoGRAM or 
UK Biobank. If this is the case then estimates from the two-sample Mendelian randomization analyses may be 
biased towards the estimate obtained from conventional methods (e.g. multivariable regression).19 
We ran three additional analyses: first, a weighted median approach14 which is consistent even when up to half 
of the information comes from invalid instrumental variables; second, a maximum likelihood15 approach which 
uses linear relationship between the risk factor and outcome and a bivariate normal distribution for the genetic 
association estimates; finally, inverse variant weighting (IVW) to combine each of the three SNPs which is a 
linear regression analysis through the mean SNP-exposure and SNP-outcome results that is forced to go through 
zero (i.e. constrained to have intercept zero).16 As a sensitivity analysis to explore horizontal pleiotropy we used 
MR-Egger regression16, which is similar to IVW but does not constrain the regression line to go through zero. A 
non-zero intercept in MR-Egger suggests possible horizontal pleiotropy; the slope can be interpreted as the 
effect having relaxed the horizontal pleiotropy assumption. To investigate how pleiotropy might be influencing 
our estimates we performed multivariable Mendelian randomization17 which uses multiple genetic variants 
associated with more than one risk factor to simultaneously estimate the causal effect of each of the risk factors 
on the outcome. 
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Supplemental Tables 
Table S1. Association of plasma cortisol with CVD in the combined VIP, MONICA and MSP cohort and BWHHS cohort with the same individuals in each model 
 
 
VIP, MONICA and MSP BWHHS 
Cases Controls OR (95% CI) p Cases Controls OR (95% CI) p 
Unadjusted 
323 492 1.16 (0.99 to 1.35) 0.07 154 313 0.95 (0.78 to 1.16) 0.78 
Adjusted 
323 492 1.19 (1.01 to 1.41) 0.04 154 313 0.99 (0.80 to 1.22) 0.92 
Unadjusted and 
0700h-1100h 
268 396 1.19 (0.99 to 1.43) 0.06 45 89 1.21 (0.80 to 1.83) 0.36 
Adjusted and 0700h-
1100h 
268 396 1.31 (1.07 to 1.60) 0.009 45 89 1.13 (0.72 to 1.76) 0.59 
 
OR, odds ratio; CI, confidence intervals; p, p value. All models included the matching variables of age; for VIP, MONICA and MSP, all models included the matching 
variables of sex, study, and baseline assessment date. Adjusted models also included BMI, smoking and time of sampling in the regression models. Analyses were repeated 
restricted to individuals with blood sampling time between 0700h and 1100h. 
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Table S2. Effect of including each confounder one-at-a-time on the associations of plasma cortisol with CVD in the combined VIP, MONICA and MSP cohort and 
BWHSS cohort with the same individuals in each model 
 
VIP, MONICA and MSP BWHHS 
Cases Controls OR (95% CI) p Cases Controls OR (95% CI) p 
All sampling times included: 
Unadjusted 323 492 1.16 (0.99 to 1.35) 0.07 154 313 0.95 (0.78 to 1.16) 0.62 
+ BMI 323 492 1.20 (1.02 to 1.40) 0.03 154 313 0.97 (0.79 to 1.18) 0.73 
+ Smoking 323 492 1.16 (0.99 to 1.36) 0.07 154 313 0.93 (0.77 to 1.14) 0.49 
+ Time of sampling 323 492 1.14 (0.96 to 1.34) 0.13 154 313 0.99 (0.81 to 1.21) 0.90 
Adjusted 323 492 1.19 (1.01 to 1.41) 0.04 154 313 0.99 (0.80 to 1.22) 0.92 
Sampling time restricted to 0700h -1100h: 
Unadjusted 268 396 1.19 (0.91 to 1.43) 0.06 45 89 1.21 (0.80 to 1.83) 0.36 
+ BMI 268 396 1.26 (1.04 to 1.53) 0.02 45 89 1.23 (0.81 to 1.87) 0.33 
+ Smoking 268 396 1.19 (0.99 to 1.44) 0.06 45 89 1.16 (0.76 to 1.76) 0.50 
+ Time of sampling 268 396 1.22 (1.00 to 1.48) 0.04 45 89 1.17 (0.76 to 1.79) 0.48 
Adjusted 268 396 1.31 (1.07 to 1.60) 0.01 45 89 1.13 (0.72 to 1.76) 0.59 
 
OR, odds ratio; CI, confidence intervals; p, p value. All models included the matching variables of age; for VIP, MONICA and MSP, all models included the matching 
variables of sex, study, and baseline assessment date. Adjusted models also included BMI, smoking and time of sampling in the regression models. Analyses were repeated 
restricted to individuals with blood sampling time between 0700h and 1100h. 
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Table S3. Effect of including each confounder one-at-a-time on the associations of plasma cortisol with CVD in the imputed dataset of the combined VIP, MONICA 
and MSP cohort  
 
VIP, MONICA and MSP 
Cases Controls OR (95% CI) P 
All sampling times included: 
Unadjusted 905 1717 1.00 (0.91 to 1.09) 0.91 
+ BMI 905 1717 1.03 (0.94 to 1.13) 0.53 
+ Smoking 905 1717 1.01 (0.92 to 1.10) 0.81 
+ Time of sampling 905 1717 1.00 (0.91 to 1.11) 0.95 
Adjusted 905 1717 1.06 (0.96 to 1.17) 0.24 
Sampling time restricted to 0700h - 1100h: 
Unadjusted 702 1109 1.05 (0.94 to 1.17) 0.39 
+ BMI 702 1109 1.10 (0.98 to 1.23) 0.12 
+ Smoking 702 1109 1.06 (0.95 to 1.19) 0.30 
+ Time of sampling 702 1109 1.05 (0.94 to 1.18) 0.41 
Adjusted 702 1109 1.12 (0.99 to 1.26) 0.07 
 
OR, odds ratio; CI, confidence intervals; p, p value. All models included the matching variables of age, sex, study and baseline assessment date. Analyses were repeated 
restricted to individuals with blood sampling time between 0700h and 1100h. 
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Table S4. Missing data in the VIP, MONICA and MSP cohort 
Variable Missing, n (%) 
Plasma cortisol 0 (0) 
Sampling time 1371 (52.3) 
BMI 69 (2.6) 
Smoking 97 (3.7) 
Sex 0 (0) 
Age 0 (0) 
Survey date 0 (0) 
Cohort 0 (0) 
Fasting glucose 266 (10.1) 
Leptin 42 (1.6) 
BMI, body mass index. 
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Table S5. Associations with missing sampling time in the VIP, MONICA and MSP cohort 
 No missing sampling time 
(n=1251) 
Missing sampling time 
(n=1371) 
p 
Cortisol, nmol/l 528 (185) 524 (187) 0.59 
Age, years 54.5 (7.3) 54.2 (8.3) 0.43 
Male 873 (70) 1018 (74) 0.01 
BMI, kg/m2 26.5 (3.9) 26.1 (3.6) 0.002 
Smoking 291 (24) 238 (25) 0.72 
Case-control cohort 
    Castro1 152 (12) 130 (9)  
    Castro2 474 (38) 318 (23)  
    FIA1 90 (7) 100 (7)  
    FIA2 535 (43) 823 (60) <0.001 
Case (MI or stroke) 445 (36) 460 (34) 0.28 
MI 230 (52) 306 (67) <0.001 
Ischemic stroke 178 (83) 128 (83) 0.94 
Survey Date, days (SD) 12139 (838) 11891 (943) <0.001 
Fasted >8 hours 1000 (80) 665 (49) <0.001 
HDL cholesterol, nmol/l 1.40 (1.39) 1.27 (0.36) 0.10 
Total cholesterol, nmol/l 6.29 (1.26) 6.03 (1.29) 0.81 
Fasting glucose, nmol/l 5.55 (1.46) 5.36 (1.24) 0.0006 
Postload glucose, nmol/l 6.75 (1.99) 6.62 (2.10) 0.10 
Hypertension 660 (59) 666 (55) 0.07 
Leptin, nmol/l 9.49 (9.40) 8.20 (7.92) 0.0002 
BMI, body mass index; MI, myocardial infarction; SD, standard deviation; p, p value. For continuous variables the mean and SD are presented; for binary variables the 
number and percentage are presented. Castro1, Castro2, FIA1 and FIA2 are case-control studies within the VIP, MONICA and MSP cohort. 
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Table S6. Variables used in multivariable imputation models in the VIP, MONICA and MSP cohort 
Variable Type of variable Model used to predict missing data in this variable Classification of variable to predict missing data in other variables 
Case Binary N/A no missing Binary 
Cortisol Continuous N/A no missing Continuous 
Sex Binary N/A no missing Binary 
Age Continuous N/A no missing Continuous 
Survey date Continuous N/A no missing Continuous 
Cohort Categorical N/A no missing Categorical 
Smoking Binary Logistic regression Binary 
BMI Continuous Linear regression Continuous 
Sampling time Continuous Linear regression (truncated lower limit of 0) Continuous 
Log transformed fasting glucose Continuous Linear regression Continuous 
Log transformed leptin Continuous Linear regression Continuous 
BMI, body mass index. 
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Table S7. Distributions of imputed variables in the imputed datasets and in the observed data (with no imputation) in the VIP, MONICA and MSP cohort 
 % data 
imputed 
Distribution 
Mean (SD) for continuous variables 
% for categorical variables 
  Imputed datasets Observed (with no missing) dataset 
Sampling time (minutes from 0700h) 52.3 144.9 (113.9) 129.0 (103.4) 
BMI (kg/m2) 2.6 26.3 (3.8) 26.3 (3.8) 
Smoking 3.7 24.7 24.5 
Fasting glucose 10.1 1.67 (0.19) 1.67 (0.19) 
Leptin 1.6 1.84 (0.80) 1.84 (0.80) 
BMI, body mass index. 
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Table S8. Association of plasma cortisol with CVD in the imputed dataset of the VIP, MONICA and MSP cohort 
 
VIP, MONICA and MSP 
Cases Controls OR (95% CI) p 
Unadjusted 905 1717 1.00 (0.91 to 1.09) 0.91 
Adjusted 905 1717 1.06 (0.96 to 1.17) 0.24 
Unadjusted and 0700h-1100h 702 1109 1.05 (0.94 to 1.17) 0.39 
Adjusted and 0700h-1100h 702 1109 1.12 (0.99 to 1.26) 0.07 
 
OR, odds ratio; CI, confidence intervals; p, p value. All models included the matching variables of age, sex, study, and baseline assessment date. Adjusted models also 
included BMI, smoking and time of sampling in the regression models. The analyses using the imputed data include 2622 participants. Analyses were repeated restricted to 
individuals with blood sampling time between 0700h and 1100h for which sample sizes vary between 1811 and 1958. 
 
  
13 
 
Table S9. Case classification and covariates included in the multivariable regression of prospective studies meta-analysis 
Study Outcome Case classification Covariates included in regression model 
VIP, MONICA and MSP3,4 Fatal CVD 
 
Non-fatal CVD 
 
ICD 8 and 9 codes: 414 and 798–799 
ICD 10: I25 and R96–99 
ICD 8 and 9 codes: 410-413 and 430-438 
ICD 10 codes: I20-I24 and I60-69 
Age, sex, study, baseline assessment date, smoking, 
BMI and time of sampling 
BWHHS20 Fatal CHD 
Non-fatal CHD 
 
ICD10 codes: I20-I25, I51.6 
MI (defined according to WHO criteria), first diagnosis 
of angina or coronary artery by-pass or angioplasty. 
Age, smoking, BMI and time of sampling 
Caerphilly8 Fatal IHD 
Non-fatal IHD 
ICD-9 codes: 410 to 414 
ICD-9 codes: 410 to 414 
Age, smoking, adult social class, alcohol consumption, 
height, FEV1/height2, fibrinogen, white cell count 
Vietnam Experience Study9 Fatal CVD 
 
ICD-9 codes: 390–434 and 436–448 
ICD-10 codes: I00–I78 
None 
ICD, International Classification of Disease 
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Table S10. Leave one out meta-analysis of prospective multivariable regression association of morning plasma cortisol with cardiovascular disease 
Excluded study OR (95% CI) 
VIP, MONICA and MSP 1.13 (1.01 to 1.27) 
BWHHS 1.21 (1.04 to 1.39) 
Caerphilly 1.31 (1.11 to 1.53) 
Vietnam 1.16 (1.04 to 1.29) 
D+L pooled estimate 1.18 (1.06 to 1.31) 
OR, odds ratio; CI, confidence interval; D+L, DerSimonian and Laird. 
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Table S11. Association of the genetic variants comprising the instrumental variable for morning plasma cortisol used in the Mendelian randomization analyses with 
potential confounders included in multivariable regression models in the VIP, MONICA and MSP cohort 
 Age, years 
(95% CI) 
Sex 
(95% CI) 
Survey date, days 
(95% CI) 
Cohort 
(95% CI) 
BMI 
(95% CI) 
Sampling time, 
minutes (95% CI) 
Smoking 
(95% CI) 
rs12589136 -0.27 (-0.81 to 0.28) -0.08 (-0.23 to 0.08) 21.69 (-40.08 to 83.46) 0.04 (-0.04 to 0.11) -0.20 (-0.47 to 0.06) -1.76 (-11.91 to 8.39) 0.10 (-0.06 to 0.26) 
rs2749529 -0.20 (-0.63 to 0.24) -0.03 (-0.15 to 0.10) 29.90 (-18.91 to 78.71) 0.05 (-0.02 to 0.11) -0.02 (-0.23 to 0.19) -0.31 (-8.61 to 7.98) 0.06 (-0.07 to 0.19) 
rs11621961 0.05 (-0.40 to 0.49) 0.01 (-0.11 to 0.14) 26.95 (-23.54 to 77.43) -0.03 (-0.09 to 0.03) -0.03 (-0.24 to 0.19) -5.77 (-14.15 to 2.60) -0.03 (-0.16 to 0.11) 
Fixed-effects 
(IV pooled ES) -0.13 (-0.39 to 0.14) -0.02 (-0.10 to 0.05) 26.82 (-3.69 to 57.33) 0.02 (-0.02 to 0.06) -0.07 (-0.20 to 0.06) -2.70 (-7.80 to 2.40) 0.04 (-0.04 to 0.12) 
Random-effects 
(D+L pooled ES) -0.13 (-0.39 to 0.14) -0.02 (-0.10 to 0.05) 26.82 (-3.69 to 57.33) 0.02 (-0.03 to 0.07) -0.07 (-0.20 to 0.06) -2.70 (-7.80 to 2.40) 0.04 (-0.04 to 0.12) 
CI, confidence interval; IV, inverse variance; ES, effect size; D+L, DerSimonian and Laird. Effect estimates are the difference in means per allele associated with higher 
morning plasma cortisol 
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Table S12. Association between the genetic instrumental variable for morning plasma cortisol with morning plasma cortisol and potential confounders in publicly 
available GWAS consortia 
Outcome Consortium Year Effect estimate LCI UCI p 
Morning plasma cortisol  CORNET  2014 0.090 0.070 0.100 6·05e-28 
Ever vs never smoked   TAG  2010 -0.009 -0.024 0.006 0.263 
Cigarettes smoked per day   TAG  2010 -0.106 -0.210 -0.001 0.047 
Total cholesterol   GLGC  2013 -0.006 -0.012 0.000 0.054 
HDL cholesterol   GLGC  2013 -0.002 -0.008 0.004 0.489 
LDL cholesterol   GLGC  2013 -0.007 -0.013 0.000 0.042 
Triglycerides   GLGC  2013 0.003 -0.003 0.009 0.305 
Fasting glucose   MAGIC  2010 -0.004 -0.008 0.001 0.140 
2hr glucose   MAGIC  2010 0.003 -0.021 0.026 0.828 
Type 2 diabetes   DIAGRAM  2014 0.019 0.003 0.035 0.021 
Waist-to-hip ratio   GIANT  2015 0.005 -0.001 0.010 0.092 
Overweight   GIANT  2013 -0.013 -0.025 -0.002 0.019 
Weight   GIANT  2013 -0.007 -0.016 0.001 0.068 
Waist circumference   GIANT  2015 0.002 -0.003 0.007 0.486 
Obesity class 1   GIANT  2013 -0.010 -0.026 0.005 0.184 
Obesity class 2   GIANT  2013 -0.001 -0.025 0.022 0.907 
Obesity class 3   GIANT  2013 -0.002 -0.046 0.042 0.921 
Body mass index   GIANT  2015 0.000 -0.004 0.005 0.874 
Body fat   NA  2016 0.004 -0.002 0.011 0.204 
LCI, 95% lower confidence interval; UCI, 95% upper confidence interval; HDL, high density lipoprotein; LDL, low density lipoprotein. Effect estimates are either the log 
Odds ratio (for binary outcome) or mean difference (for continuous outcome) from a random-effects meta-analysis. If multiple studies exist, the association if from the largest 
sample in a European population.  
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Table S13. Association of morning plasma cortisol on CHD from alternative two-sample Mendelian randomization approaches 
Method OR (95% CI) 
Weighted mode 1·06 (0·94 to 1·19) 
Maximum likelihood 1·06 (0·98 to 1·15) 
Inverse variance weighted 1·06 (0·98 to 1·15) 
Weighted median 1·06 (0·96 to 1·17) 
MR-Egger – slope; intercept 0·80 (0·43 to 1·49); 0·03, se 0·03, p=0·53 
OR, odds ratio; CI, confidence interval; MR, Mendelian randomization; se, standard error; p, p value. 
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Table S14. Association of morning plasma cortisol on CHD adjusting for possible risk factors from two-sample multivariable Mendelian randomization analyses 
Exposures No. of SNPs OR LCI UCI p 
Morning plasma cortisol 3 1.04 0.94 1.15 0.44 
Type 2 Diabetes 46 1.09 1.06 1.12 9.89E-13 
Morning plasma cortisol 3 1.09 0.97 1.22 0.16 
Overweight 20 1.20 1.14 1.26 1.68E-11 
Morning plasma cortisol 3 1.04 0.73 1.48 0.83 
Cigarettes per day 6 0.98 0.95 1.00 0.09 
Morning plasma cortisol 3 1.03 0.93 1.14 0.56 
LDL Cholesterol 303 1.47 1.41 1.52 2.33E-97 
SNP, single nucleotide polymorphism; OR, odds ratio; LCI, 95% lower confidence interval; UCI, 95% upper confidence interval; p, p value; LDL, low density lipoprotein. 
Morning plasma cortisol from CORNET consortium (n=12,597). Overweight (BMI) from GIANT consortium (cases=93,015, controls=65,840).  Cigarettes smoked per day 
from TAG consortium (n=68,028). LDL cholesterol from GLGC (n=173,082). 
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Supplemental Figure 
Figure S1. Funnel plot of log odds ratio (logOR) against the standard error of log odds ratio (se logOR) to assess potential small study bias in the meta-analysis of 
prospective studies 
 
